Ensysce Biosciences, Inc.
About Ensysce Biosciences, Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $5.1M
- Net income
- $2.4M
- Total assets
- $7.5M
- Market cap
- $3.7M
- Operating margin
- -202.1%
- Net margin
- -200.8%
Source: SEC EDGAR · updated Jun 8, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $5.1M
- Operating expenses
- $15.3M
- Operating income
- -$10.2M
- Net income
- -$10.2M
- EPS (basic)
- $-3.98
- EPS (diluted)
- $-3.98
Balance sheet
- Total assets
- $7.5M
- Current assets
- $7.2M
- Total liabilities
- $4.6M
- Current liabilities
- $4.6M
- Shareholders’ equity
- $2.9M
Cash flow
- Operating cash flow
- -$7.8M
- Investing cash flow
- -$931.9K
- Financing cash flow
- $8.7M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $3.7M
- EPS (diluted)
- $-3.98
- Shares outstanding
- 14.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 1, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $2.4M in FY2025.
- Revenue grew 43% from FY2021 to FY2025.
- Trading 90% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Ensysce Biosciences, Inc..
Write a review
News about Ensysce Biosciences, Inc.
News & sentiment via Polygon.io
